MedTrace Logo

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

NCT03274778 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-11-18

No results posted yet for this study

Summary

Ruxolitinib will be dispensed to patients candidate to prostatectomy immediately after histological diagnosis of prostate adenocarcinoma. The treatment will be given for 28 days followed by a prostatectomy thereafter.

Tumor material and blood samples will be analysed before, during and after the treatment with Ruxolitinib.

Conditions

Interventions

DRUG

Ruxolitinib 20 MG

tablets

Sponsors & Collaborators

  • Oncology Institute of Southern Switzerland

    lead OTHER

Principal Investigators

  • Andrea Alimonti, Prof. · Institute of Oncology Research (IOR)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2020-03-24
Completion
2020-03-24

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03274778 on ClinicalTrials.gov